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Abstract We cloned in silico a novel human UDP-GalNAc:-
polypeptide N-acetylgalactosaminyltransferase (pp-GalNAc-T),
pp-GalNAc-T12. The deduced amino acid sequence of pp-Gal-
NAc-T12 contains all conserved motifs in pp-GalNAc-T family
proteins. Quantitative real time polymerase chain reaction anal-
ysis revealed that the pp-GalNAc-T12 transcript was expressed
mainly in digestive organs such as stomach, small intestine and
colon. The recombinant pp-GalNAc-T12 transferred GalNAc to
the mucin-derived peptides such as the Muc1a, Muc5AC, EA2
peptides and the GalNAc-Muc5AC glycopeptide. Since mucins
are glycoproteins mainly produced in the digestive organs, our
results suggest that pp-GalNAc-T12 plays an important role in
the initial step of mucin-type oligosaccharide biosynthesis in
digestive organs. . 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Mucin-type O-linked oligosaccharides are linked to a serine
or threonine residue on the acceptor protein via an N-acetyl-
galactosamine residue at their reducing end. The enzyme,
UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase
(pp-GalNAc-T) (EC 2.4.1.41), catalyzes the initial step of mu-
cin-type oligosaccharide biosynthesis by transferring GalNAc
from UDP-GalNAc to a hydroxyl amino acid on a polypep-
tide acceptor [1]. To date, 11 distinct members have been
identi¢ed in mammals [2^17]. Each isoform exhibits a di¡er-
ent tissue distribution and substrate speci¢city. However, the
substrate speci¢city of each isoform and the hierarchical net-
work of glycosyltransferases are poorly understood.
A search of the human and murine expressed sequence tag
(EST) database revealed numerous new sequence homologues,
suggesting that an even larger and more complex pp-GalNAc-
T family exists in mammals [12]. Thus, the isolation and char-
acterization of pp-GalNAc-Ts are essential for the further
study of O-glycosylation.
Here, we report they, pp-GalNAc-T12. The pp-GalNAc-
T12 transcript was expressed mainly in digestive organs, and
the recombinant pp-GalNAc-T12 transferred GalNAc to tan-
dem repeats of mucins in vitro.
2. Materials and methods
2.1. Cloning of human pp-GalNAc-T12 cDNA
By performing a BLAST search of EST databases, we found three
cDNAs (GenBank accession number: AK024865, BE677813,
AI800923) homologous to the open reading frame (ORF) of human
pp-GalNAc-T4 (Y08564). On searching the human genomic DNA
database, we found that a genomic sequence (AL136084) contained
a putative initial codon and a transmembrane domain at positions
5286^5397 and aligned to BE677813 at positions 5484^5685. Based
on the database gene working, the full ORF of this putative pp-Gal-
NAc-T was predicted to be 1746 bp. The full-length sequence of this
putative pp-GalNAc-T was deposited into GenBank with the acces-
sion number AB078146.
The cDNA encoding the full-length ORF was obtained by polymer-
ase chain reaction (PCR) using the Expand1 High Fidelity PCR
system (Roche), Marathon-Ready1 cDNA of human lung (Clontech)
as a template, and primers (forward 5P-GGGGACAAGTTTGTA-
CAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGTGGGG-
GCGCACGGCGCGGCGG-3P and reverse 5P-GGGGACCACTTT-
GTACAAGAAAGCTGGGTCTCATAACATGCGCTCTTTGAAG-
AACCA-3P). PCR was performed according to the manual supplied.
The forward and reverse primers have attB1 and attB2 overhangs,
respectively, to create the recombination sites. The ampli¢ed fragment
was subcloned into the pDONR1201 vector using the BP CLONASE
Enzyme Mix (Invitrogen). Finally, an entry clone containing a com-
plete ORF, sharing complete homology with the EST clone, was ob-
tained and given the designation pp-GalNAc-T12.
2.2. Quantitative analysis of the pp-GalNAc-T12 transcripts in human
tissues and cell lines by real time PCR
For the quanti¢cation of pp-GalNAc-T12 transcripts, we employed
the quantitative real time PCR method using TaqMan0 Universal
PCR Master Mix and ABI PRISM 7700 Sequence Detection System
(Applied Biosystems), as described in detail previously [18]. Mara-
thon-Ready0 cDNAs of various human tissues were purchased
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from Clontech. The cDNAs from various tumor cell lines were gen-
erated in our laboratory [19].
The primer set and probe for pp-GalNAc-T12 were as follows: the
forward primer, 5P-CGTGCCCGCTTGGAAC-3P, the reverse primer,
5P-TGTTCTGGAGCATCCCGAAG-3P, and the probe, 5P-TGGGG-
ATGTGACAGAGAGGAAGCAGCT-3P with a minor groove binder
[20]. The PCR conditions included one cycle at 50‡C for 2 min, one
cycle at 95‡C for 10 min, and 50 cycles at 95‡C for 15 s, and 60‡C for
1 min. The relative amount of pp-GalNAc-T12 transcript was nor-
malized by the amount of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) transcript in the same cDNA.
2.3. Production of recombinant pp-GalNAc-T12
To develop the recombinant pp-GalNAc-T12 encoding the putative
catalytic domain, the truncated pp-GalNAc-T12 cDNA, starting at
amino acid position 60, was generated by PCR using primers (forward
5P-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCGGCGCG-
AGCCGGTCATGCCGCGGC-3P and reverse 5P-GGGGACCACTT-
TGTACAAGAAAGCTGGGTCTCATAACATGCGCTCTTTGAA-
GAACCA-3P). PCR was carried out with these primers, human lung
Marathon-Ready1 cDNA as a template, and an Expand1 High Fi-
delity PCR system. The ampli¢ed DNA fragment was subcloned into
pDONR1201 using attB1 and attB2 sequences in primers as de-
scribed previously [18]. Then, the truncated cDNA fragment of pp-
GalNAc-T12 was transferred between the attR1 and attR2 sites of an
expression vector, pFBIF, using the LR CLONASE Enzyme Mix
(Invitrogen) from pDONR1201 vector.
Bacmid DNA from pFBIF-GalNAc-T12-transformed DH10BAC
competent cells (Invitrogen) was transfected into Sf21 insect cells
(BD Pharmingen). Recombinant virus was prepared according to
the instruction manual of the BAC to BAC Baculovirus Expression
Systems (Invitrogen). Sf21 insect cells were infected with recombinant
virus to yield secreted recombinant pp-GalNAc-T12 protein. Then,
the culture media were harvested and incubated overnight at 4‡C
Table 1
Acceptor substrates of peptides
Non-glycosylated peptide One GalNAc-glycosylated peptide (by pp-GalNAc-T) Peptide sequence
Muc1a GalNAc-Muc1a (T6) FAM-AHGVT*SAPDTR
Muc2 GalNAc-Muc2 (T2) PTTTPITTTTTVTPTPTPTGTQTK-FAM
Muc5AC GalNAc-Muc5AC (T2) FAM-GTTPSPVPTTSTTSA
Muc7 GalNAc-Muc7 (T13)** PTPSATT*PAPPSSSAPPETTAAK-FAM
EA2 GalNAc-EA2 (T13)** PTTDSTT*PAPTTK-FAM
*: Represents the site where one GalNAc residue attached. Unmarked means not identi¢ed. All of the glycopeptides were identi¢ed by mass.
**: Refers to a novel human pp-GalNAc-T (Zhang and Narimatsu, unpublished).
Fig. 1. A: Nucleotide and amino acid sequence of pp-GalNAc-T12. The nucleotides are numbered from the ¢rst nucleotide of the initiation co-
don. The predicted amino acid sequence is presented below the putative nucleotide coding sequence. A triangle represents the truncated posi-
tion. Positions of exon^intron junctions are indicated by vertical arrows. B: ClustalW alignment for comparison of pp-GalNAc-T12 with the
other pp-GalNAc-Ts. Multiple sequence analysis (ClustalW) of the human GalNAc-T. The putative transmembrane domains are underlined.
Asterisks indicate the amino acids identical among all proteins. Three motifs of GT1, Gal/GalNAc transferase and lectin motif are indicated
above the sequences underlined. Conserved amino acids are shown by dots.
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with anti-FLAG M1 antibody-conjugated resin (Sigma). The protein^
resin mixtures were washed twice in the bu¡er containing 50 mM
Tris^HCl, pH 7.4, 150 mM NaCl, and 1 mM CaCl2. Then the re-
combinant protein was eluted with 50 mM Tris-bu¡ered saline con-
taining 1 mM EDTA.
The soluble forms of the truncated human pp-GalNAc-T2 and -T6,
containing amino acid residues 52^571 (T2) and 53^622 (T6), respec-
tively [2,5], were also produced by the same method.
The puri¢ed recombinant enzymes were detected by Western blot-
ting with anti-FLAG monoclonal antibody after sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis separation to determine rela-
tive amounts. Each puri¢ed pp-GalNAc-T was adjusted to the same
amount according to the results of Western blotting, and was sub-
jected to pp-GalNAc-T assay.
2.4. Analysis of pp-GalNAc-T activity of recombinant human
pp-GalNAc-T12
Reactions for the pp-GalNAc-T assay were performed at 37‡C in a
20 Wl mixture containing 25 mM Tris^HCl (pH 7.4), 5 mM MnCl2,
0.2% Triton X-100, 0.25 mM UDP-GalNAc (Sigma), an appropriate
5-carboxy£uorescein succinimidyl ester (FAM)-labeled acceptor sub-
strate, and the puri¢ed enzyme. 50 pmol of acceptor substrate and
125 ng of enzyme were used for time course reactions (Fig. 4A,B);
and 1/10 of the substrates and enzymes were used for primary and
secondary enzyme reactions (Fig. 4C). The reaction was terminated by
boiling for 3 min, and then subjected to High performance liquid
chromatography (HPLC) on a reverse C18 column (Cosmosil 5C18-
AR, 4.6U250 mm) as previously described [18]. FAM-labeled oligo-
peptides, that represent the tandem repeats of Muc1, Muc2, Muc5AC,
Muc7, and EA2 [21^25], respectively, were purchased from Sawady
Co., Ltd. (Tokyo, Japan), and were used as acceptor substrates. Pep-
tides of Muc1a, Muc2, Muc5AC, Muc7 and EA2 with one GalNAc
residue attached, prepared by glycosylation using pp-GalNAc-T2,
-T6, or -T13 (Zhang and Narimatsu, unpublished) followed by puri-
¢cation by HPLC, were used as GalNAc-glycopeptide acceptor sub-
strates for the pp-GalNAc-T assay (Table 1).
2.5. Matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-TOF) and amino acid sequencing of glycopeptide
products
In order to determine the glycosylation site of the product of the
pp-GalNAc-T12 reaction, the glycopeptide isolated by HPLC was
subjected to MALDI-TOF mass spectrometry using REFLEX1 IV
(Bruker Daltonics, Tsukuba, Japan) and Edman degradation on a
protein sequencer PPSQ-23A (Shimadzu). The methods for mass spec-
trometry (MALDI-TOF) and amino acid sequencing were described
in our previous paper [18].
3. Results
3.1. Isolation of pp-GalNAc-T12 cDNA
The cDNA of a new member of the pp-GalNAc-Ts family
was cloned by the method described in Section 2, and desig-
nated human pp-GalNAc-T12. The nucleotide and the de-
duced amino acid sequences of pp-GalNac-T12 are shown
in Fig. 1A, and an alignment of the amino acid sequences
of nine pp-GalNAc-Ts was generated using ClustalW as
shown in Fig. 1B. The pp-GalNAc-T12 gene encodes 581
Fig. 1 (Continued).
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amino acids, a typical type II membrane protein, comprising
an N-terminal cytoplasmic domain, a transmembrane domain,
a putative stem region and a catalytic domain containing a
GT1 motif, Gal/GalNAc transferase motif and ricin-like lectin
motif (Fig. 1B) [26]. These motifs, commonly observed in the
pp-GalNAc-T family, were present in the predicted positions
in the putative amino acid sequence of pp-GalNAc-T12.
The pp-GalNAc-T12 gene was localized in a draft genome
sequence (GenBank1 accession number AL136084) that was
mapped to human chromosome 9 at q22. The ORF of pp-
GalNAc-T12 was composed of 10 exons.
The phylogenic tree of pp-GalNAc-Ts was generated by the
neighbor joining method [27] based on the amino acid sequen-
ces (Fig. 2). The branch length indicates the evolutionary dis-
tance between family members. pp-GalNAc-T12 shares ap-
proximately 32V56% homology with the other mammalian
pp-GalNAc-Ts in amino acid sequence, and is most homolo-
gous to human pp-GalNAc-T4.
3.2. Distribution of pp-GalNAc-T12 transcripts in human
tissues and cell lines
The expression levels of the pp-GalNAc-T12 transcript in
various human tissues and cell lines were determined by the
real time PCR method. pp-GalNAc-T12 was expressed in
most tissues (Fig. 3A) and in various cell lines (Fig. 3B),
although at di¡erent levels. Tissues with a considerably high
level of expression were the small intestine, stomach, pancreas,
and colon. Moderate expression was observed in the testis,
thyroid gland and spleen. The expression levels in the remain-
ing tissues tested were very low or undetectable. pp-GalNAc-
T12 was expressed at a relatively low level or undetectable in
the cell lines tested. The expression levels of pp-GalNAc-T12
in colon and stomach cancer cell lines (Fig. 3B) were lower
than those in colon and stomach (Fig. 3A), respectively.
3.3. Di¡erent substrate speci¢cities of pp-GalNAc-T12 from
those of the known pp-GalNAc-Ts
To analyze the pp-GalNAc-T activity, the recombinant pp-
GalNAc-T12, an approximately 66 kDa secreted protein, was
produced in Sf21 cells, puri¢ed from culture supernatant, and
subjected to pp-GalNAc-T assay. The puri¢ed recombinant
pp-GalNAc-T12, UDP-GalNAc, and a panel of acceptor sub-
strates were incubated for various periods, and the products
generated were analyzed by HPLC.
First, Muc1a-derived peptide (FAM-AHGVTSAPDTR)
was incubated with pp-GalNAc-T12, and was analyzed by
HPLC. As demonstrated in Fig. 4A, the substrate peak
(shown as ‘S’) was gradually consumed and another peak
(shown as ‘P’) appeared as the incubation time for either
GalNAc-T reaction was extended, indicating that pp-Gal-
NAc-T12 transferred GalNAc to Muc1a peptide. Incubation
with pp-GalNAc-T12 generated only one shifted peak for the
Muc1a peptide, suggesting that only one Ser/Thr residue was
glycosylated by T12. The product of pp-GalNAc-T12 was
isolated by HPLC and subjected to MALDI-TOF mass spec-
trometry and protein sequencing. The product was identi¢ed
to have one GalNAc at the ¢fth threonine (data not shown).
In contrast to the case of the Muc1a peptide, the reaction
products of pp-GalNAc-T12 toward the Muc5AC-derived
peptide (FAM-GTTPSPVPTTSTTSA) showed multiple peaks
as demonstrated in Fig. 4B. One tall shifted peak appeared on
HPLC of the Muc5AC peptide after a short incubation with
pp-GalNAc-T12. This peak was gradually consumed and mul-
tiple shifted peaks appeared as the incubation time was in-
creased. This result indicates that pp-GalNAc-T12 transferred
GalNAc to multiple sites in the Muc5AC peptide [28].
To further identify the catalytic speci¢city of pp-GalNAc-
T12, we assayed peptides derived from EA2, Muc2, and Muc7
(Fig. 4C-1). pp-GalNAc-T12 exhibited enzymic activity to-
ward EA2, but negligible activity toward Muc2 and Muc7.
pp-GalNAc-T12 transferred GalNAc to multiple sites in
Muc5AC, suggesting that pp-GalNAc-T12 has a secondary
GalNAc-T activity. To elucidate the secondary GalNAc-T
activity of pp-GalNAc-T12, we generated mono-GalNAc-
transferred mucin peptides and used them for the GalNAc-
T assay with pp-GalNAc-T12. As demonstrated in Fig. 4C-2,
the incubation with pp-GalNAc-T12 generated shifted peaks
only in the GalNAc-Muc5AC peptide, whereas T12 generated
no or very few shifted peak in GalNAc-transferred EA2,
Muc1a, Muc2, and Muc7. These results indicate that pp-Gal-
NAc-T12 has a di¡erent catalytic speci¢city from pp-GalNAc-
T4 and -T7 which have a strong secondary activity as reported
by others [4,6].
Thus, pp-GalNAc-T12 exhibited comparable GalNAc-T ac-
tivity toward non-glycosylated peptides: Muc5AC, Muc1a
and EA2, and no detectable activity with Muc2 and Muc7.
pp-GalNAc-T12 showed enzymatic activity toward the Gal-
NAc-Muc5AC glycopeptide, but no detectable activity to
mono-GalNAc-glycosylated Muc1a, Muc2, Muc7 and EA2.
These ¢ndings depict a novel and unique catalytic speci¢city
of pp-GalNAc-T12.
4. Discussion
The initiation of O-glycosylation is catalyzed by a family of
pp-GalNAc-Ts. Studies over the past decade have found a
Fig. 2. A phylogenetic tree of pp-GalNAc-Ts. A phylogenetic tree
of pp-GalNAc-Ts was constructed by the neighbor joining method
based on amino acid sequences. The branch length indicates the
evolutionary distance between each member.
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family of pp-GalNAc-Ts that display di¡erences in both their
substrate speci¢city and their patterns of tissue distribution.
In the present study, we have cloned and characterized a
novel isoform of the pp-GalNAc-T family, designated pp-Gal-
NAc-T12. Although pp-GalNAc-T12 was expressed in vari-
ous tissues and cell lines, the expression level of its gene was
especially high in digestive organs such as the small intestine,
stomach, pancreas, and colon, suggesting that potential sub-
strates of pp-GalNAc-T12 are mucin proteins which are
mainly secreted from the digestive tract [29].
Each pp-GalNAc-T displays a unique pattern of expression
across human and rodent tissues; pp-GalNAc-T1, -T2, -T3
and -T6 are expressed in a broad range of tissues; while others
are more restricted in their expression patterns. For example,
the pp-GalNAc-T4 transcript is highly expressed in rodent
sublingual gland, stomach, and colon, with lower levels in
the small intestine, urogenital track, and lung [14]. The ex-
pression of pp-GalNAc-T7 is similar to that of pp-GalNAc-
T4 [16].
The expression level of pp-GalNAc-T12 was low in tumor
cell lines. Consistent with the result for pp-GalNAc-T12, pp-
GalNAc-T1 and -T2 were also expressed at lower levels in cell
lines derived from the pancreas, colon, stomach, and breast
compared to the original tissues [30].
pp-GalNAc-T isoforms have catalytic speci¢city toward ac-
ceptor substrates, although such speci¢city overlaps and each
enzyme may accommodate a rather broad range of substrates
[31]. Prior glycosylation of a speci¢c serine or a threonine in a
peptide substrate also in£uences the acquisition of sugar at
vicinal positions [32], strongly suggesting that O-glycosylation
of multisite substrates proceeds in a speci¢c hierarchical man-
ner. Therefore, one can classify a pp-GalNAc-T through the
determination of its catalytic speci¢city. Synthetic peptides
have been commonly used as acceptor substrates for in vitro
O-glycosylation reactions to determine the substrate speci¢city
of pp-GalNAc-Ts [31].
In the present study, pp-GalNAc-T12 showed primary ac-
tivity when the peptide (AHGVTSAPDTR) derived from
Muc1a was used as a substrate [21,33]. Muc1 is expressed
on the apical surface of mucous epithelial cells almost
Fig. 3. Quantitative analysis of the pp-GalNAc-T12 transcript in human tissue (A) and tumor cell lines (B) by real time PCR. Standard curves
for pp-GalNAc-T12 and GAPDH were generated by serial dilution of each plasmid DNA. The expression level of the pp-GalNAc-T12 tran-
script was normalized to that of the GAPDH transcript which was measured in the same cDNAs. Values are expressed as copy numbers of the
target gene in 1 Wg of total RNA. Data were obtained from triplicate experiments and are indicated as the meanUS.D.
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throughout the body [34]. It was reported that the glycosyla-
tion of the Muc1a peptide by human GalNAc-T1, -T2, and
-T3 resulted in only one glycoform that was glycosylated at
Thr in GVTSA as evaluated by MALDI-TOF and amino acid
sequencing [21,32]. The remaining sites, Ser in GVTSA and
Thr in PDTR, cannot be glycosylated by these enzymes, but it
has been shown that the ‘¢ll-up’ reactions are catalyzed by pp-
GalNAc-T4, which has a preference for peptides partially
modi¢ed by GalNAc incorporations by other pp-GalNAc-Ts
[4,6]. pp-GalNAc-T12 generated only one product from the
Muc1a peptide, that is, the same product produced by pp-
GalNAc-T1, -T2 and -T3. pp-GalNAc-T12 has only primary
activity toward the Muc1a peptide like pp-GalNAc-T1, -T2
and -T3 [21].
The Muc5AC gene is also highly expressed in the gastro-
intestinal tract, the lungs, the nervous system and bone [35].
The mucin motif peptide substrate (GTTPSPVPTTSTTSA)
deduced from the human Muc5AC gene [23] consists of six
threonine residues including a XTPXP sequence that was re-
ported as a signal favoring e⁄cient glycosylation. It was re-
ported that pp-GalNAc-T1, -T2, and -T3 transferred two, one
and three GalNAcs to Muc5AC, respectively [36]. Our results,
accumulation of the ¢rst product in Fig. 4B, indicate that pp-
GalNAc-T12 transfers GalNAc rapidly to one preferential site
in the Muc5AC peptide, and then slowly to the other residues.
Because the peaks generated by pp-GalNAc-T12 toward the
naked Muc5AC peptide and the mono-GalNAc-Muc5AC
were similar, the ¢rst glycosylation by pp-GalNAc-T2 did
not a¡ect the primary pp-GalNAc-T12’s activity. It is sug-
gested that pp-GalNAc-T12 prefers a di¡erent residue in the
Muc5AC peptide from the residue preferred by pp-GalNAc-
T2.
pp-GalNAc-T12 showed comparative levels of activity to-
ward naked and mono-GalNAc-Muc5AC peptides. However,
pp-GalNAc-T12 showed very weak or no activity for Gal-
NAc-EA2 or GalNAc-Muc1a, whereas pp-GalNAc-T12
showed relatively high activity toward naked EA2 or
Muc1a. These results suggested that the presence of one or
two GalNAc-Thr moieties in the substrate signi¢cantly re-
duced this enzymic activity, consistent with the report of a
signi¢cant reduction in pp-GalNAc-T1 enzymic activity on
prior glycosylation of the Muc2 glycopeptide [37].
pp-GalNAc-T12 shares approximately 56% homology with
the human pp-GalNac-T4. However, the acceptor substrate
Fig. 4. A: HPLC analysis of in vitro O-glycosylation of Muc1a by puri¢ed recombinant pp-GalNAc-T12. The panel shows the elution pro¢les
of Muc1a peptide glycosylated by pp-GalNAc-T12. Peak S corresponds to the original substrate, non-glycosylated Muc1a peptide. Peak P cor-
responds to the products, having a single GalNAc at the ¢fth threonine, of the enzyme reaction. The incubated time of recombinant enzymes
is indicated at the left of the panels. B: HPLC analysis of in vitro O-glycosylation of Muc5AC by puri¢ed recombinant pp-GalNAc-T12. The
panel shows the elution pro¢les of Muc5AC peptide glycosylated by pp-GalNAc-T12. Peak S corresponds to the original substrate, non-glyco-
sylated peptide. Peak P corresponds to the products of the enzyme reaction. The incubated time of recombinant enzymes is demonstrated.
C: HPLC analysis of in vitro O-glycosylation of a panel of non-glycosylated peptides and mono-glycosylated glycopeptide by pp-GalNAc-T12.
Panels 1 and 2 show the elution pro¢les of non-glycosylated peptide and mono-glycosylated glycopeptide before and after incubation with pp-
GalNAc-T12 to 6 h, respectively. Peak S corresponds to the original substrate, non-glycosylated peptide. Peak P corresponds to the products
of the enzyme reaction.
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speci¢cities of the two isoforms are totally di¡erent, and
showed di¡erent patterns of activity with these naked or gly-
cosylated peptide substrates. Although pp-GalNAc-T4
showed very weak activity for naked Muc1 and Muc5AC
peptides and a weak activity with Muc2 peptide, pp-Gal-
NAc-T4 showed signi¢cantly enhanced activity for GalNAc-
incorporated peptide substrates, indicating that pp-GalNAc-
T4 can utilize the remaining acceptor site [4,6]. In contrast,
pp-GalNAc-T12 showed negligible activity or no enhance-
ment of activity with the GalNAc-Muc1a, -Muc2 and
-Muc7 glycopeptides. pp-GalNAc-T4 also utilized non-glyco-
sylated Muc7 peptide, but demonstrated no e¡ect of prior
glycosylation on the Muc7 peptide, while pp-GalNAc-T12
showed very weak primary activity with Muc7 and no detect-
able activity for GalNAc-Muc7 glycopeptide [6]. Thus, human
pp-GalNAc-T12 is clearly distinguishable from pp-GalNAc-
T4.
In summary, pp-GalNAc-T12 has primary pp-GalNAc-T
activity toward the peptide substrates Muc1a, Muc5AC and
EA2; as well as mono-GalNAc-Muc5AC generated through
glycosylation by pp-GalNAc-T2. pp-GalNAc-T12 can also
transfer GalNAc to multiple sites in the Muc5AC peptide.
In contrast, pp-GalNAc-T12 has very weak or no pp-Gal-
NAc-T activity toward naked and mono-GalNAc-Muc2 and
-Muc7, mono-GalNAc-Muc1a and -EA2. The substrate spec-
i¢city of pp-GalNAc-T12 illustrates the novel catalytic speci-
¢city among the pp-GalNAc-T family, and suggests a role for
pp-GalNAc-T12 in the hierarchical network of O-glycosyla-
tion.
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